At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)
In Brief
A Phase 1 clinical trial evaluating AZD7451 for Glioblastoma Multiforme. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Background: \- AZD7451 is a drug that may help interfere with brain tumor cell growth. It can prevent glioma cells from entering into normal brain tissue, and slow or stop the growth of additional tumors. Researchers want to see if AZD7451 is effective against gliomas that have not responded to surgery, radiation, or chemotherapy. Objectives: \- To see if AZD7451 is a safe and effective treatment for gliomas that have not responded to standard treatments. Eligibility: \- Individuals at least 18 years of age who have gliomas that have not responded to standard treatments. Design: * Participants will be screened with a physical exam, medical history, blood and urine tests, heart function tests, an eye exam, and imaging studies. * Participants will take AZD7451 daily by mouth for 28-day cycles of treatment. * Participants will keep a medication diary and record any side effects. Treatment will be monitored with frequent blood tests and imaging studies. * Treatment will continue as long as there are no serious side effects and the tumor does not start growing again....
Study Details
Timeline
Interventions
Depending on dose level, AZD7451 will be given once daily for 28 day cycles.